Balance Sheet

Accounts Payables Accumulated Expenses Assets Cash & Current Investments Cash & Equivalents Common Equity Current Assets Current Deferred Revenue Current Leases Finished Goods Inventory Liabilities and Shareholders Equity Liabilities from Discontinued Operations Liabilities from Discontinued Operations Long-Term Deferred Tax Long-Term Investments Non-Current Assets Non-Current Debt Notes Payables Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Preferred Stock Liabilities Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Work In Process

Cash Flow Statement

Daily Values

Growth Metrics

Dna X (SONM) Long-Term Deferred Tax (2024 - 2025)

Dna X filings provide 2 years of Long-Term Deferred Tax readings, the most recent being $1.4 million for Q4 2025.

On a quarterly basis, Long-Term Deferred Tax rose 2151.56% to $1.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.4 million, a 2151.56% increase, with the full-year FY2025 number at $1.4 million, up 2151.56% from a year prior.
Long-Term Deferred Tax hit $1.4 million in Q4 2025 for Dna X, up from $64000.0 in the prior quarter.
In the past five years, Long-Term Deferred Tax ranged from a high of $1.4 million in Q4 2025 to a low of $64000.0 in Q4 2024.